Bill to require parental review of FDA medication guides for psychotropic drugs draws opposition from Medicaid officials, medical society

The Senate Health and Human Services committee heard testimony on House Bill 732, which would require prescribers to present FDA medication guides and obtain written informed consent from a parent or guardian before prescribing psychotropic drugs to Medicaid‑covered children.

Rep. Clayne Cordelli introduced the bill, saying parents should be aware of risks associated with psychotropic medications, including suicidal ideation, aggression and other serious side effects that are described in FDA medication guides. "Parents should be aware of those risks before allowing their children to take them," Cordelli said.

Officials from the Department of Health and Human Services provided an informational presentation and raised multiple practical concerns. Jonathan Ballard, chief medical officer at DHHS, said the state27s Medicaid program has long treated medical care agnostically to payer type and that adding a payer‑specific requirement creates operational difficulties. He said many medications beyond traditional psychotropics include language in FDA labels about neuropsychiatric effects, which would broaden the bill27s scope beyond common clinical expectations. Ballard also noted that many providers do not know a patient27s payer at the time of prescribing, and that Medicaid often becomes the payer retrospectively for some patients, complicating who the statute would apply to.

State Medicaid staff projected the legislation would impose substantial administrative costs. Deputy Medicaid Director David Chorney and Rob Berry, general counsel for the division of Medicaid, described the workload associated with auditing claims, performing manual chart reviews to verify that the required written consent occurred, and carrying out the suspension and appeal processes that would be required if providers were found noncompliant. The department said it would provide a revised fiscal note to quantify those costs; a preliminary estimate in materials that accompanied testimony put a possible range of state costs at roughly $1 million to $2.5 million for oversight and enforcement activities and for potential medical cost changes tied to access shifts.

The New Hampshire Medical Society testified in opposition. Kathy Stratton, the society27s CEO, told the committee that physicians already have informed‑consent conversations in office visits and that the bill would impose heavy administrative burdens and raise access concerns by creating a different standard for Medicaid patients. She also noted that FDA medication guides are sometimes lengthy and not written for easy readability; she said the patient‑physician informed‑consent conversation is more effective than simply distributing a long printed document.

Committee questions tracked those issues: members asked whether existing consent practices might already cover the bill27s intent; how the statute would apply in emergency or inpatient settings; and whether a payer‑specific statutory duty would be feasible in a clinic where payer status is not always immediately known. DHHS and the Medical Society both emphasized that the standard of care already requires a risk‑benefit discussion when prescribing medications and that existing licensing and disciplinary systems can address deviations.

Why it matters: The bill attempts to increase parental transparency for children on Medicaid receiving medications with psychiatric effects. But DHHS and physician groups warned that creating a Medicaid‑only prescribing requirement could add administrative cost, complicate urgent care and emergency responses, and potentially reduce access if some providers decline to treat Medicaid patients under a new legal regime.

What27s next: DHHS said it will supply a more detailed fiscal analysis; the committee did not take action and heard both supportive testimony from the sponsor and significant practical objections from Medicaid administrators and the medical society.